Vfend (Voriconazole) Patent Expiration, LOE Window & CMS Spending
Vfend (Voriconazole) by Pfizer: Off-Patent Genericized (AB Competition), 14 AB generics, $243K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N021266 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 14 |
| 2024 CMS Total Public Spend | $243K |
| 2024 Medicare Part D Spend | $8K |
| 2024 Medicaid Spend | $235K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.